Business Wire

Diligent Announces “Diligent One,” the Only Integrated Platform Providing a Unified and Connected GRC Experience

14.9.2023 16:30:00 EEST | Business Wire | Press release

Share

Diligent, a leading GRC SaaS company, today announced Diligent One, a first-of-its-kind platform that provides leadership, boards and practitioners with a single source for all their governance, risk and compliance (GRC) needs. The platform was announced live today at Modern Governance Summit, the world’s premier GRC event, and is available in pilot phase now.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230914836526/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Diligent One platform. (Graphic: Business Wire)

Over the last six months Diligent has launched board and leadership reporting dashboards for ESG, Audit, Cyber Risk and Investor Engagement to bring clear and consistent insight into organizations’ risk posture. With Diligent One, users have the ability to customize and create dashboards using company data and systems. Combined with Diligent’s best-in-class solutions across governance, risk, compliance, audit and ESG, customers now have a connected view of risk management and the ability to capture and contextualize data and insights and report to the board — all within a single platform.

“In order to see the big picture, you need to start with data. Yet often that data is in spreadsheets or a number of systems accessed by many different applications. This is where risk lives — in the unconnected dots and spaces between siloed systems,” said Brian Stafford, President and CEO of Diligent, during his keynote speech at Modern Governance Summit. “In our conversations with customers over the years, the one constant has been that they are inundated with data and solutions. This is why we are so excited to bring our customers the only platform on the market that provides a single source of truth for all your GRC needs.”

“In today’s fast-moving business environment, obtaining access to high-quality governance data is essential to understanding and meeting the needs of a diverse set of stakeholders,” said Lili Mehta, Senior Vice President and Global Head of Glass Lewis’ Corporate Business. “Board directors and executives now require a unified view of their data so they can more effectively analyze and report to their stakeholders. By delivering meaningful information, companies can proactively manage a wide range of issues and maintain a competitive edge.”

Diligent One is the only platform to deliver automated analyses of virtually any data and provide continuous monitoring of identified areas of risk, allowing organizations to reduce manual work, build actionable insights and expand risk coverage while saving time and money.

“The risk landscape is expanding and evolving at an increasing rate, and understanding the specific risks that could materially impact the business has become more difficult as a result,” said Adam Bailey, SVP and Global Head of Product at Diligent. “A fragmented approach to GRC is no longer sustainable for organizations. An integrated platform is key to providing the insights needed to drive company performance and ensure operational health.”

Learn more about the Diligent One platform here.

About Diligent

Diligent is a leading GRC SaaS company that gives organizations the tools and solutions they need to bring clarity to complex risk, elevate impactful insights and get ahead of a world that is constantly changing. With solutions across governance, risk, compliance, audit and ESG, Diligent empowers more than 1 million users and 700,000 board members and leaders to make better decisions, faster. No matter the challenge. Learn more at diligent.com.

Follow Diligent on LinkedIn, Twitter and Facebook.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For More Information: 
Julia Hanbury 
Senior Communications Manager, Diligent  
+1 (604) 669-4225
Jhanbury@diligent.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye